Logo

ONCO

Onconetix, Inc.

ONCO

Onconetix, Inc. • NASDAQ
$2.73 ▲ 17.38% (+0.41)
Market Cap $1.56 M
52w High $179.35
52w Low $2.10
Dividend Yield 0%
P/E 0
Volume 89.22K
Outstanding Shares 570.78K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $303.651K ▲ $2.338M ▲ $-8.784M ▼ -2.893K% ▼ $-6.25 ▼ $-8.48M ▼
Q2-2025 $106.494K ▲ $2.006M ▼ $-2.372M ▲ -2.228K% ▲ $-4.76 ▲ $-2.146M ▲
Q1-2025 $101.63K ▼ $12.617M ▼ $-8.546M ▲ -8.409K% ▼ $-1.802K ▼ $-8.318M ▲
Q4-2024 $711.976K ▲ $29.806M ▲ $-29.438M ▼ -4.135K% ▼ $-17.38 ▼ $-29.989M ▼
Q3-2024 $406.859K $2.751M $-3.827M -940.72% $-2.93 $-3.295M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $836.556K ▲ $19.679M ▲ $16.303M ▲ $3.374M ▼
Q2-2025 $283.515K ▼ $19.119M ▲ $13.209M ▼ $5.91M ▲
Q1-2025 $1.577M ▲ $18.776M ▼ $14.258M ▼ $4.517M ▼
Q4-2024 $646.5K ▲ $28.182M ▼ $18.571M ▼ $9.611M ▼
Q3-2024 $341.495K $61.919M $20.897M $33.912M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-8.784M ▼ $-3.178M ▼ $0 $4.291M ▲ $553.041K ▲ $-3.178M ▼
Q2-2025 $-2.372M ▲ $-1.41M ▲ $0 $744.574K ▼ $-1.294M ▼ $-1.41M ▲
Q1-2025 $-8.546M ▲ $-2M ▼ $0 ▲ $2.87M ▲ $930.693K ▲ $-2M ▼
Q4-2024 $-29.438M ▼ $-917.647K ▲ $-3.874K ▼ $1.303M ▲ $305.005K ▲ $-921.521K ▲
Q3-2024 $-3.827M $-1.147M $-2.313K $578.643K $-589.046K $-1.149M

Five-Year Company Overview

Income Statement

Income Statement Onconetix is essentially still pre‑revenue. Over several years it has reported no meaningful sales and a steady pattern of small operating and net losses. This means the business is still in the investment and build‑out phase rather than generating a recurring income base. The large swings in earnings per share mostly reflect share structure changes, not a sudden shift in business performance. Overall, the income statement shows a company spending modestly to operate but not yet bringing in product revenue to offset those costs.

Balance Sheet

Balance Sheet The balance sheet is very light, with only a small pool of assets, limited equity, and a bit of debt. Cash levels have recently been extremely thin, which can constrain flexibility and may increase reliance on external funding. There is not much of a buffer to absorb setbacks, so the company’s financial position appears fragile and highly dependent on future capital raises and successful commercialization of its products.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, though the absolute amounts are small. There is effectively no spending on long‑term assets, and free cash flow is negative, reflecting that the company consumes cash rather than generates it. Taken together, the cash‑flow profile looks like an early‑stage biotech: ongoing operating outflows, no internal cash engine yet, and a need for continued financing to support operations.

Competitive Edge

Competitive Edge Onconetix focuses on men’s health and oncology with two main products: Entadfi, a treatment for enlarged prostate, and Proclarix, a prostate cancer diagnostic. Entadfi aims to differentiate through its dual‑action mechanism that targets symptoms and disease progression while aiming to lessen sexual side effects. Proclarix targets a clear pain point in urology by trying to better distinguish aggressive cancers and reduce unnecessary biopsies, supported by a commercialization agreement with a major lab company. However, the firm is small, operates in competitive therapeutic and diagnostic markets, and has recently experienced corporate and listing‑related challenges, which can weaken its perceived competitive standing despite the scientific promise of its products.

Innovation and R&D

Innovation and R&D The company’s innovation is centered on combining known mechanisms in a differentiated way for BPH (Entadfi) and using biomarker‑based algorithms for more refined prostate cancer risk assessment (Proclarix). Its subsidiary’s ability to license manufacturing know‑how to other diagnostics firms also points to solid technical depth. That said, beyond these flagship assets, the future R&D pipeline is not clearly articulated, and earlier references to a broader vaccine and oncology pipeline appear uncertain under the new strategy. Future value from innovation will depend heavily on how Onconetix clarifies and executes its next wave of clinical or diagnostic programs and whether it can secure partners to share risk and resources.

Summary

Onconetix is a very early‑stage, commercially oriented biotech with two notable men’s health and oncology offerings but virtually no revenue to date and a very thin financial cushion. The company’s science and product concepts appear differentiated, particularly in better diagnosing clinically significant prostate cancer and offering a potentially more tolerable BPH therapy. At the same time, the financials highlight a business that is still in the build‑and‑prove phase, reliant on external funding and successful product uptake. Key uncertainties revolve around its ability to ramp sales, maintain listing and governance stability, and define a robust, longer‑term pipeline beyond the current core products.

NEWS

October 30, 2025 · 9:00 PM UTC

Onco-Innovations Appoints Jared Rushton to Board of Directors

Read more

September 26, 2025 · 8:30 AM UTC

Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.

Read more

September 26, 2025 · 8:15 AM UTC

Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement

Read more

September 22, 2025 · 8:00 AM UTC

Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM

Read more